Oak Study Efficacy
THE LONGEST MEDIAN OS OF ~14 MONTHS OBSERVED IN ITT
More than half of patients were alive at 1 year with TECENTRIQ1
Superior survival regardless of PD-L1 expression1,2
Median OS Regardless of PDL-1 Expression
IC=tumour-infiltrating immune cell; ITT=intent to treat; TC=tumour cell.
Tecentriq©: Superior 2-years overall survival with durable benefit
TECENTRIQ®: DURABLE RESPONSE IN PREVIOUSLY TREATED ADVANCED NSCLC
Median DOR more than doubled with TECENTRIQ1
DOR=duration of response; NE=not estimable.
- Median follow-up time was 19 months
1. TECENTRIQ prescribing information.
2. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
MatCode Approval No.: -1905-V2-3253